Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M610153200 on December 22, 2006

J. Biol. Chem., Vol. 282, Issue 8, 5356-5366, February 23, 2007
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/8/5356    most recent
M610153200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kapoor, M.
Right arrow Articles by Crofford, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kapoor, M.
Right arrow Articles by Crofford, L. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Microsomal Prostaglandin E Synthase-1 Deficiency Is Associated with Elevated Peroxisome Proliferator-activated Receptor {gamma}

REGULATION BY PROSTAGLANDIN E2 VIA THE PHOSPHATIDYLINOSITOL 3-KINASE AND AKT PATHWAY*

Mohit Kapoor{ddagger}, Fumiaki Kojima{ddagger}, Min Qian§, Lihua Yang{ddagger}, and Leslie J. Crofford{ddagger}1

From the {ddagger}Department of Internal Medicine, Rheumatology Division, University of Kentucky, Lexington, Kentucky 40536 and the §Department of Ophthalmology and Visual Sciences, Division of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, Michigan 48109

Received for publication, October 30, 2006 , and in revised form, December 22, 2006.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
mPGES-1 (microsomal PGE synthase-1) is an inducible enzyme that acts downstream of cyclooxygenase (COX) and specifically catalyzes the conversion of prostaglandin (PG) H2 to PGE2 under basal as well as inflammatory conditions. In this study, using mouse embryo fibroblasts (MEFs) isolated from mice genetically deficient for the mPges-1 gene, we show basal elevation of peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) expression (protein and mRNA) and transcriptional activity associated with reduced basal PGE2. We further show that basal mPGES-1-derived PGE2 suppresses the expression of PPAR{gamma} through a cAMP-independent pathway involving phosphatidylinositol 3-kinase and Akt signaling. Using specific PPAR{gamma} agonist (rosiglitazone), PPAR{gamma} ligand (15-deoxy-{Delta}12,14-PGJ2), and PPAR{gamma} inhibitor (GW9662), we confirm that activation of PPAR{gamma} blocks interleukin-1beta-induced up-regulation of COX-2, mPGES-1, and their derived PGE2. Furthermore, we demonstrate that up-regulation of PPAR{gamma} upon genetic deletion of mPGES-1 is responsible for reduced COX-2 expression under basal as well as interleukin-1beta-stimulated conditions. This study provides evidence for the first time that mPGES-1 deletion not only decreases proinflammatory PGE2 but also up-regulates anti-inflammatory PPAR{gamma}, which has the ability to suppress COX-2 and mPGES-1 expression and PGE2 production. Thus, mPGES-1 inhibition may limit inflammation by multiple mechanisms and is a potential therapeutic target.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Prostaglandins (PGs)2 are formed by metabolism of arachidonic acid by cyclooxygenases (COX) to generate an intermediate substrate, PGH2, which is further metabolized by terminal synthases to generate specific PGs (1, 2). mPGES-1, originally known as microsomal glutathione S-transferase 1-like 1 (MGST1-L1), is an inducible enzyme that acts downstream of COX and specifically catalyzes the conversion of PGH2 to PGE2 (3), most prominently in inflammatory conditions (4, 5). However, we have recently shown that mPGES-1 is critical for PGE2 production under basal as well as inflammatory conditions (6).

mPGES-1 is coordinately induced with COX-2 by inflammatory stimuli in a variety of cells and tissues (4, 7). PGE2 is the most abundant PG associated with inflammatory conditions, and overproduction of PGE2 coincides with increased COX-2 and mPGES-1 expression (4, 7). PGE2 exerts the majority of its actions through a family of G protein-coupled receptors, including EP1, EP2, EP3, and EP4 (8). The effects of PGE2 via these receptors are mediated through various downstream signaling pathways, including cAMP-dependent protein kinase, mitogen-activated protein kinase (MAP kinase), phosphatidylinositol 3-kinase (PI 3-kinase), and Akt (8–10).

Inhibition of PGE2 production and action is associated with reduction of the pain and inflammation associated with a wide variety of diseases. Nonselective and COX-2-selective nonsteroidal anti-inflammatory drugs (NSAIDs) block PGE2 production by inhibiting the activity of COX and are extensively used to treat arthritis and other inflammatory conditions. However, side effects associated with the inhibition of COX-2 (11–13) have revived efforts to develop safer anti-inflammatory drugs. mPGES-1 is an attractive target to achieve more specific inhibition of PGE2 production associated with inflammatory disorders while preserving production of other PGs. Specific inhibitors of mPGES-1 are yet not available; however, studies using mice genetically deficient in mPGES-1 have demonstrated that this enzyme is a key mediator of inflammation, pain, angiogenesis, fever, bone metabolism, and tumorigenesis (14–17). Our studies also demonstrate that mPGES-1 expression is increased in tissues and cells of various inflammatory conditions, including rheumatoid arthritis and osteoarthritis (4, 5, 18, 19). Previous studies have also shown that mPGES-1 null mice are resistant to arthritis in the models of collagen-induced arthritis and collagen antibody-induced arthritis (14, 15).

Peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) is a member of nuclear hormone receptor superfamily of ligand-activated transcription factors that have been shown to regulate inflammatory responses and assist in the resolution of inflammation (20–24). Recent studies have shown a close relationship between PPAR{gamma} and PGs in the regulation of inflammation (25–27). However, until now, no study has evaluated the potential role of mPGES-1 in the regulation of PPAR{gamma}. We created mouse embryo fibroblast (MEF) cell lines derived from mPGES-1 null mice and wild type (WT) littermates to facilitate these studies. This study demonstrates for the first time that mPGES-1 deficiency and reduced PGE2 lead to elevation of PPAR{gamma} under basal conditions. This study further identifies key downstream signaling targets responsible for PPAR{gamma} regulation by mPGES-1-derived PGE2.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Animals—mPGES-1 heterozygous mice on a DBA1 lac/J background were obtained from Pfizer (15). Mice were housed in microisolator cages in a pathogen-free barrier facility, and all experiments were performed under the approved IACUC and institutional guidelines.

Materials—Rabbit anti-human mPGES-1 antiserum was a gift from Dr. Per-Johan Jakobsson (Karolinska Institute, Stockholm, Sweden). PPAR{gamma} transcription assay kit, rabbit anti-mouse COX-2 polyclonal antibody, PGE2, carbacyclin, NS-398 (N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide), rosiglitazone, (15-deoxy-{Delta}12,14-PGJ2), GW9662, LY294002, ovine COX-2 standard protein, and enzyme-linked immunosorbent assay (ELISA) kit for PGE2 were all purchased from Cayman Chemical Co. (Ann Arbor, MI). PD98059 (selective inhibitor of MAP kinase kinase (MEK)), SB203580 (specific inhibitor of p38 MAP kinase), and 1L-6-hydroxymethyl-chiro-inositol-2-(R)-2-O-methyl-3-O-octadecylcarbonate (specific Akt inhibitor) were purchased from Calbiochem. Mouse monoclonal PPAR{gamma} primary antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse anti-human beta-actin monoclonal antibody and indomethacin were obtained from Sigma. Horseradish peroxidase-conjugated goat anti-rabbit IgG and horseradish peroxidase-conjugated goat anti-mouse IgG were obtained from Jackson ImmunoResearch. Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were from Invitrogen. Recombinant mouse IL-1beta was obtained from R&D Systems (Minneapolis, MN). TRIpure was purchased from Roche Diagnostics. The polyvinylidene difluoride membrane and enhanced chemiluminescence (ECL) reagent were purchased from Amersham Biosciences.

Preparation and Activation of Mouse Embryo Fibroblasts—Embryos were harvested from mPGES-1 (DBA1 lac/J) pregnant heterozygous females (E12.5) who had been mated with heterozygous males. Whole embryos were minced and placed into culture DMEM containing 10% FBS, 100 units/ml penicillin, and 100 µg/ml streptomycin at 37 °C under an atmosphere of 5% CO2. At confluence, the cells were detached and passaged, and 3–4 passage cells were used in all experiments. MEFs were plated into the wells of a 6-well plate at a density of 3 x 105 cells/well in DMEM containing 10% FBS. Cells were starved for 72 h in DMEM containing 1% FBS and then incubated with or without 1 ng/ml IL-1beta in the presence or absence of various treatments for 12 h. Cell viability was determined by measuring mitochondrial NADH-dependent dehydrogenase activity with WST-1 assay (Dojindo Laboratories, Kumamoto, Japan).

Reverse Transcription (RT)-PCR—RNA from the cells was extracted with TRIpure reagent according to the manufacturer's instructions. Reverse transcription was performed according to the manufacturer's instructions using a SuperScript preamplification system (Invitrogen) with 1 µg of total RNA from the cells as a template. Subsequent amplifications of the cDNA fragments by PCR with HotStar Taq polymerase (Qiagen, Valencia, CA) were performed using 0.5 µl of the reverse-transcribed mixture as a template with specific oligonucleotide primers and cycle numbers as follows: mouse PPAR{gamma} (31 cycles), sense 5'-CCT CTC CGT GAT GGA AGA CC-3' and antisense 5'-GCA TTG TGA GAC ATC CCC AC-3'; mouse GAPDH (20 cycles), sense 5'-GGG GTG AGG CCG GTG CTG AGT AT-3' and antisense 5'-CAT TGG GGG TAG GAA CAC GGA AGG-3'. After initial denaturation at 95 °C for 15 min, PCR involved amplification cycles of 30 s at 95 °C, 30 s at 56 °C, and 45 s at 72 °C, followed by elongation for 5 min at 72 °C. The amplified cDNA fragments were resolved by electrophoresis on 2% (w/v) agarose gel and were visualized under UV light using a Chemidoc apparatus (Bio-Rad) after staining of the gel with ethidium bromide.

Western Blotting—Cells were lysed in Tris-buffered saline (TBS) containing 0.1% SDS, and the protein content of the lysates was determined using bicinchoninic acid (BCA) protein assay reagent (Pierce) with bovine serum albumin as the standard. Cell lysates were adjusted to equal equivalents of protein and then were applied to SDS-polyacrylamide gels (10–20%) for electrophoresis. Next, the proteins were electroblotted onto polyvinylidene difluoride membranes. After the membranes were blocked in 10 mM TBS containing 0.1% Tween 20 (TBS-T) and 5% skim milk, the membranes were probed for 1.5 h with the respective antibodies (1:1000 for mPGES-1, COX-2, PPAR{gamma}, and beta-actin) in TBS-T for 1.5 h. After washing the membranes with TBS-T, the membranes were incubated with horseradish peroxidase-conjugated anti-rabbit (for mPGES-1 and COX-2) or horseradish peroxidase-conjugated anti-mouse (for PPAR{gamma} and beta-actin) IgG (1:10,000 dilution in TBS-T containing 5% skim milk) overnight at 4 °C. After further washing with TBS-T, protein bands were visualized with an ECL Western blot analysis system using a Chemidoc apparatus (Bio-Rad).

PPAR{gamma} Transcriptional Activity Assay—MEFs were plated into the T-75 flasks at a density of 2 x 106 cells/flask in DMEM containing 10% FBS. Cells were starved for 72 h in DMEM containing 1% FBS and then incubated with or without 1 ng/ml IL-1beta in the presence/absence of various treatments. Nuclear extraction and PPAR{gamma} transcriptional activity assays were performed using the PPAR{gamma} transcription assay kit (Cayman Chemicals, Ann Arbor, MI), and procedures were followed according to the manufacturer's recommendation.

Measurement of PGE2 in Culture Medium—MEFs were incubated for 12 h in the presence or absence of IL-1beta (1 ng/ml). In experiments involving treatment with indomethacin and NS-398, these compounds were added 72 h before IL-1beta stimulation. The culture supernatant was harvested, and concentration of PGE2 was measured by ELISA (Cayman Chemical, Ann Arbor MI). Assays were performed according to the manufacturer's recommendation.


Figure 1
View larger version (29K):
[in this window]
[in a new window]

  		FIGURE 1.
Effect of mPGES-1 deletion on PPAR{gamma} expression (mRNA and protein) and transcriptional activity in IL-1beta-stimulated and unstimulated MEFs. mPGES-1 WT and null MEFs were incubated with or without IL-1beta (1 ng/ml) for 12 h. a, mRNA levels of PPAR{gamma} (30 cycles) and GAPDH (20 cycles) from mPGES-1 WT and null MEFs were determined by RT-PCR. Mean ± S.E. for PPAR{gamma} expression normalized with GAPDH from n = 3 separate embryo lines is shown. *, mPGES-1 null MEFs compared with mPGES-1 WT MEFs. Cont, control. b, PPAR{gamma} and beta-actin protein expressions were determined by Western blotting. Mean ± S.E. for PPAR{gamma} expression normalized with beta-actin from n = 5 separate embryo lines is shown. *, mPGES-1 null MEFs compared with mPGES-1 WT MEFs. c, PPAR{gamma} transcriptional activity was measured in the nuclear extracts of IL-1beta-stimulated and unstimulated mPGES-1 WT and null MEFs. Open bars represent mPGES-1 WT MEFs, and closed bars represent mPGES-1 null MEFs. PPAR{gamma} transcriptional activity was normalized to mg of protein for each sample. Data are expressed as the mean ± S.E. for four embryo lines. * and ** indicate statistical significance at p < 0.05 and p < 0.01, respectively.

 
Statistical Analysis—The data are expressed as mean ± S.E. Statistical analysis was performed using Student's t test. p < 0.05 was considered statistically significant.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Effect of mPGES-1 Genetic Deletion on PPAR{gamma} Expression (mRNA and Protein) and Transcriptional Activity in mPGES-1 WT and Null MEFs—mPGES-1 WT and null MEFs, in the presence/absence of IL-1beta stimulation, were analyzed for PPAR{gamma} mRNA expression (Fig. 1a), protein expression (Fig. 1b), and transcriptional activity (Fig. 1c). Results showed that under basal conditions, PPAR{gamma} mRNA and protein levels were significantly higher (p < 0.05) in the mPGES-1 null MEFs compared with their WT counterparts. Similarly PPAR{gamma} transcriptional activity was significantly higher (p < 0.01) in mPGES-1 null MEFs compared with WT MEFs under basal conditions. IL-1beta stimulation decreased the levels of PPAR{gamma} mRNA, protein, and transcriptional activity by near 50% in both cell types; however, PPAR{gamma} expression and transcriptional activity levels were still significantly higher (p < 0.05) in the mPGES-1 null MEFs compared with WT MEFs. These results show that genetic deletion of mPGES-1 leads to elevation of PPAR{gamma} expression and transcriptional activity levels. Furthermore, proinflammatory signals reduce PPAR{gamma} expression and transcriptional activity, an effect mitigated in the absence of mPGES-1.

Effect of mPGES-1 Genetic Deletion on PGE2 Levels in mPGES-1 WT and Null MEFs—PGE2 levels were significantly (p < 0.05) higher in mPGES-1 WT MEFs compared with null MEFs under unstimulated conditions (Fig. 2). Upon stimulation with IL-1beta, a significant (p < 0.01) increase in the levels of PGE2 was observed in WT MEFs; however, no change in the PGE2 levels was observed in mPGES-1 null MEFs. These results clearly demonstrate that mPGES-1 is critical for PGE2 production at basal as well as stimulated conditions even though we have shown previously that both cytosolic PGES (cPGES) and mPGES-2 are expressed in these MEFs (6).

Our recent study using mPGES-1 WT and null MEFs also showed that genetic deletion of mPGES-1 not only blocks PGE2 production but also results in the elevation of 6-keto-PGF1{alpha} (stable breakdown product of prostacyclin; PGI2) under basal as well as cytokine-stimulated conditions, suggesting a shunting phenomenon within the arachidonic acid metabolic pathway upon deletion of mPGES-1 (6). In this study, we further showed that mPGES-1 genetic deletion did not have any effect on the production pattern of other PGs such as PGD2 and thromboxane B2, which remained unaltered in mPGES-1 WT and null MEFs under basal as well as cytokine-stimulated conditions.


Figure 2
View larger version (11K):
[in this window]
[in a new window]

  		FIGURE 2.
Effect of mPGES-1 genetic deletion on PGE2 production in MEFs. Levels of PGE2 in supernatants of mPGES-1 WT and null MEFs were detected by ELISA at 12-h post-IL-1beta stimulation. Open bars represent mPGES-1 WT MEFs, and closed bars represent mPGES-1 null MEFs. Data are expressed as the mean ± S.E. for four embryo lines. Cont, control. * and ** indicate statistical significance at p < 0.05 and p < 0.01, respectively.

 
Effect of Exogenous PGE2 and Carbacyclin (Prostacyclin Analogue) on PPAR{gamma} Expression and Transcriptional Activity in mPGES-1 WT and Null MEFs—To determine whether PGE2 or an alternate change induced by mPGES-1 deletion suppresses PPAR{gamma} expression and transcriptional activity in MEFs, exogenous PGE2 treatment of mPGES-1 WT and null MEFs in the presence or absence of IL-1beta stimulation was performed. Addition of PGE2 under basal conditions resulted in a significant decrease (p < 0.05) in the PPAR{gamma} expression both at mRNA and protein levels in mPGES-1 null MEFs with little or no change observed in WT MEFs (Fig. 3, a and b). In the presence of IL-1beta, a further decrease in the PPAR{gamma} mRNA expression levels was observed in both mPGES-1 WT and null MEFs. PPAR{gamma} protein expression did not show any further decrease when PGE2 was used in combination with IL-1beta.

Because our previous studies using mPGES-1 WT and null MEFs showed elevation of 6-keto-PGF1{alpha} upon genetic deletion of mPGES-1 in MEFs (6), we therefore investigated the effects of carbacyclin (PGI2 analogue) to determine the contribution of PGI2 versus PGE2 toward regulation of PPAR{gamma} expression in MEFs. However, we did not observe any changes in the protein expression levels of PPAR{gamma} in mPGES-1 WT and null MEFs upon treatment with carbacyclin (Fig. 3c).

Addition of PGE2 in the absence of IL-1beta stimulation significantly (p < 0.01) decreased PPAR{gamma} transcriptional activity levels in mPGES-1 null MEFs bringing the levels similar to mPGES-1 WT MEFs (Fig. 3d). In the presence of IL-1beta stimulation, a further significant decrease in the levels of both mPGES-1 WT (p < 0.05) and null MEFs (p < 0.01) was observed. Treatment with carbacyclin did not have any effect on PPAR{gamma} transcriptional activity in mPGES-1 WT and null MEFs. These results suggest that deletion of mPGES-1 and a subsequent decrease in PGE2 levels (and not increased PGI2) play a key role in the differential regulation of PPAR{gamma} in MEFs. In addition, these results also suggest that IL-1beta has the ability to itself regulate the expression and transcriptional activity of PPAR{gamma} and may exert other intrinsic effects on PPAR{gamma} expression and activity in addition to its ability to increase PGE2 production.

Effect of PGE2 Inhibition by NSAIDs (Indomethacin and NS-398) on PPAR{gamma} Expression and Transcriptional Activity in mPGES-1 WT and Null MEFs—To further confirm the contribution of PGE2 toward differential regulation of PPAR{gamma} expression and transcriptional activity, mPGES-1 WT and null MEFs were treated with NSAIDs, including indomethacin (nonselective COX inhibitor) and NS-398 (selective COX-2 inhibitor). Addition of indomethacin and NS-398 significantly increased the levels of PPAR{gamma} protein expression (Fig. 4a) and transcriptional activity (Fig. 4b) in mPGES-1 WT MEFs only, raising the levels similar to that of mPGES-1 null MEFs. These results further confirm that PGE2 is the key mediator involved in differential regulation of PPAR{gamma} in mPGES-1 WT and null MEFs.

Effect of mPGES-1 Deletion on cAMP Levels in mPGES-1 WT and Null MEFs—PGE2 has been shown to mediate some of its downstream effects via cAMP-dependent pathways (8). Therefore, we investigated the effect of mPGES-1 deletion and the subsequent decrease in the levels of PGE2 on cAMP levels in mPGES-1 WT and null MEFs. Results showed that mPGES-1 deletion did not have any significant effect on the levels of cAMP in MEFs under basal conditions (Fig. 5a). We further investigated the effects of exogenous PGE2 and forskolin (a direct adenyl cyclase activator) on the levels of cAMP in mPGES-1 WT and null MEFs. Treatment with PGE2 (p < 0.05) and forskolin (p < 0.01) significantly increased cAMP levels in both mPGES-1 WT and null MEFs to a similar extent. These results show that the cAMP machinery is intact in both mPGES-1 WT and null MEFs.

Effect of Forskolin on PPAR{gamma} Expression and Transcription Activity Levels in mPGES-1 WT and Null MEFs—To delineate the mechanism by which PGE2 regulates PPAR{gamma} expression and transcriptional activity, we treated mPGES-1 WT and null MEFs with forskolin in the presence/absence of PGE2, and we assessed its effect on PPAR{gamma} protein expression and transcriptional activity. Forskolin did not have any effect on PPAR{gamma} protein expression (Fig. 5b) and transcriptional activity (Fig. 5c) in mPGES-1 WT and null MEFs in the absence of PGE2. However, PPAR{gamma} protein expression and transcriptional activity were significantly (p < 0.01) decreased when forskolin was used in combination with PGE2, an effect that seems to be solely elicited by PGE2 and not forskolin. These results suggest that even though cAMP pathways are activated by PGE2 and forskolin in MEFs, PGE2 regulates PPAR{gamma} expression and transcriptional activity via a signaling pathway independent of cAMP.

Effect of PI 3-Kinase Inhibitor, Akt Inhibitor, p38 Inhibitor, and MEK Inhibitor on PPAR{gamma} Expression in mPGES-1 WT and Null MEFs—PGE2 is also known to mediate some of its biological responses through MAP kinase and PI 3-kinase/Akt pathways (8). Therefore, to delineate the mechanism with which PGE2 regulates PPAR{gamma} expression in mPGES-1 WT and null MEFs, we investigated the effects of LY294002 (specific PI 3-kinase inhibitor), 1L-6-hydroxymethyl-chiro-inositol-2-(R)-2-O-methyl-3-O-octadecylcarbonate (specific Akt inhibitor), SB-203580 (selective p38 MAP kinase inhibitor), and PD98059 (selective MEK inhibitor) on PPAR{gamma} expression and transcriptional activity in mPGES-1 WT and null MEFs.


Figure 3
View larger version (35K):
[in this window]
[in a new window]

  		FIGURE 3.
Effect of PGE2 and carbacyclin on PPAR{gamma} expression (mRNA and protein) and transcriptional activity in mPGES-1 WT and null MEFs. mPGES-1 WT and null MEFs were incubated for 12 h with PGE2 (1 µM) or carbacyclin (1 µM) in the presence or absence of IL-1beta (1 ng/ml). a, mRNA levels of PPAR{gamma} (30 cycles) and GAPDH (20 cycles) from mPGES-1 WT and null MEFs were determined by RT-PCR. Mean ± S.E. for PPAR{gamma} expression normalized with GAPDH from n = 3 separate embryo lines is shown. Cont, control. *, mPGES-1 null MEFs compared with mPGES-1 WT MEFs; +, IL-beta-stimulated group compared with unstimulated controls; $, IL-beta + PGE2-stimulated group compared with unstimulated controls. b, PPAR{gamma} andbeta-actin protein expressions were determined by Western blotting. Mean ± S.E. for PPAR{gamma} expression normalized with beta-actin from n = 6 separate embryo lines is shown. *, mPGES-1 null MEFs compared with mPGES-1 WT MEFs; +, PGE2 treated group compared with their respective untreated controls; $, IL-beta + PGE2-stimulated group compared with respective unstimulated controls. c, PPAR{gamma} and beta-actin protein expressions were determined by Western blotting. Mean ± S.E. for PPAR{gamma} expression normalized with beta-actin from n = 3 separate embryo lines is shown. *, mPGES-1 null MEFs compared with mPGES-1 WT MEFs; +, PGE2-treated group compared with the irrespective untreated controls. d, PPAR{gamma} transcriptional activity was measured in the nuclear extracts of mPGES-1 WT and null MEFs treated with PGE2 or carbacyclin in the absence or presence of IL-1beta. Open bars represent mPGES-1 WT MEFs, and closed bars represent mPGES-1 null MEFs. PPAR{gamma} transcriptional activity was normalized to mg of protein for each sample. Data are expressed as the mean ± S.E. for 3–4 embryo lines. * and ** indicate statistical significance at p < 0.05 and p < 0.01 respectively.

 


Figure 4
View larger version (45K):
[in this window]
[in a new window]

  		FIGURE 4.
Effect of indomethacin and NS-398 on PPAR{gamma} protein expression (a) and transcriptional activity in mPGES-1 WT and null MEFs (b). mPGES-1 WT and null MEFs were incubated with or without indomethacin (1 µM) or NS-398 (5 µM) for 12 h. a, PPAR{gamma} and beta-actin protein expressions were determined by Western blotting. Mean ± S.E. for PPAR{gamma} expression normalized with beta-actin from n = 3 separate embryo lines is shown. Cont, control. *, mPGES-1 null MEFs compared with mPGES-1 WT MEFs; +, indomethacin-treated group compared with respective unstimulated controls; $, NS-398-treated group compared with respective unstimulated controls. b, PPAR{gamma} transcriptional activity was measured in the nuclear extracts of mPGES-1 WT and null MEFs treated with indomethacin and NS-398. Open bars represent mPGES-1 WT MEFs, and closed bars represent mPGES-1 null MEFs. PPAR{gamma} transcriptional activity was normalized to mg of protein for each sample. Data are expressed as the mean ± S.E. for three embryo lines. * and ** indicate statistical significance at p < 0.05 and p < 0.01, respectively.

 
Addition of PI 3-kinase or Akt inhibitors elevated the protein expression levels of PPAR{gamma} in mPGES-1 WT MEFs only, raising the levels similar to that observed in mPGES-1 null MEFs (Fig. 6, a and b). PI 3-kinase and Akt inhibitors in the presence of PGE2 also showed elevation in the PPAR{gamma} expression in both mPGES-1 WT and null MEFs, thus reversing the inhibitory effects of PGE2 on PPAR{gamma} expression. Addition of p38 MAP kinase and MEK inhibitors showed no effect on PPAR{gamma} protein expression in mPGES-1 WT and null MEFs in the presence or absence of PGE2 (Fig. 6c). These results clearly suggest that PI 3-kinase and Akt signaling are key downstream pathways by which PPAR{gamma} expression is suppressed by PGE2 in MEFs.

Effect of PPAR{gamma} on COX-2, mPGES-1, and PGE2 in MEFs—PPAR{gamma} is an endogenous anti-inflammatory mediator known to down-regulate key proinflammatory signals and ultimately assists in the resolution of inflammation (2, 28). Recent studies have shown that PPAR{gamma} is involved in the regulation of COX-2 and mPGES-1 expression (24, 25). To further confirm these findings in MEFs, we investigated the regulatory effects of PPAR{gamma} on COX-2 and mPGES-1 expression and PGE2 production using selective PPAR{gamma} agonist (rosiglitazone), PPAR{gamma} ligand (15-deoxy-PGJ2), and PPAR{gamma} antagonist (GW9662).

Because previous reports have shown that rosiglitazone, 15-deoxy-PGJ2, and GW9662 have the ability to affect cell viability, we therefore first determined the effects of various concentrations of these reagents on cell viability of MEFs using WST-1 assay. Concentrations of rosiglitazone (10 µM), 15-deoxy-PGJ2 (10 µM), and GW9662 (3 µM) were chosen for the subsequent experiments as these concentrations did not have any effect on cell viability of MEFs (data not shown).

Low levels of COX-2 protein were observed in unstimulated mPGES-1 WT MEFs (Fig. 7a). Upon stimulation with IL-1beta, a significant elevation (p < 0.05) in the protein expression of COX-2 was observed. Pretreatment with rosiglitazone and 15-deoxy-PGJ2 blocked up-regulated expression of COX-2 in IL-1beta-stimulated mPGES-1 WT. To confirm that rosiglitazone and 15-deoxy-PGJ2 reduced COX-2 expression via the PPAR{gamma} pathway, we incubated mPGES-1 MEFs with rosiglitazone and 15-deoxy-PGJ2 in the presence or absence of PPAR{gamma} inhibitor (GW9662). GW9662 completely reversed the inhibitory effect of rosiglitazone on COX-2 expression but showed only partial recovery on the inhibitory effect of 15-deoxy-PGJ2 on COX-2 expression in mPGES-1 WT and null MEFs. Some effects of 15-deoxy-PGJ2 have been shown previously to be mediated via alternate mechanistic pathways independent of PPAR{gamma} (26). In this study, partial recovery of COX-2 expression by GW9662 in the 15-deoxy-PGJ2 group further suggests the involvement of an alternative mechanistic pathway in addition to the PPAR{gamma} pathway by which 15-deoxy-PGJ2 blocks COX-2 expression in MEFs.

We further investigated the effects of rosiglitazone and 15-deoxy-PGJ2 on mPGES-1 expression in mPGES-1 WT MEFs. Low level of mPGES-1 protein was observed in unstimulated MEFs (Fig. 7a). Upon stimulation with IL-1beta, significant elevation (p < 0.05) in the protein expression of mPGES-1 was seen in MEFs as expected. Treatment with rosiglitazone and 15-deoxy-PGJ2 blocked the increased expression of mPGES-1 in IL-1beta-stimulated mPGES-1 WT and null MEFs. To confirm that rosiglitazone and 15-deoxy-PGJ2 reduced mPGES-1 expression via the PPAR{gamma} pathway, we incubated mPGES-1 WT MEFs with rosiglitazone and 15-deoxy-PGJ2 in the presence or absence of PPAR{gamma} inhibitor (GW9662). GW9662 significantly (p < 0.05) reversed the inhibitory effects of rosiglitazone and 15-deoxy-PGJ2 on mPGES-1 expression. These results show that increased PPAR{gamma} expression results in down-regulation of COX-2 and mPGES-1 expression under basal as well as inflammatory conditions.


Figure 5
View larger version (33K):
[in this window]
[in a new window]

  		FIGURE 5.
a, effect of mPGES-1 deletion on cAMP levels in MEFs and effect of forskolin and PGE2 on cAMP levels in mPGES-1 WT and null MEFs. Cont, control. b, effect of forskolin in the absence or presence of PGE2 on PPAR{gamma} protein expression. c, PPAR{gamma} transcriptional activity in mPGES-1 WT and null MEFs. a, cAMP levels in mPGES-1 WT and null MEFs incubated for 12 h with or without forskolin (10 µM), PGE2 (1 µM), and combination of forskolin + PGE2 were assessed by cAMP ELISA. cAMP levels were normalized to µg of protein. Open bars represent mPGES-1 WT MEFs, and closed bars represent mPGES-1 null MEFs. Data are expressed as the mean ± S.E. for four embryo lines. * and ** indicate statistical significance at p < 0.05 and p < 0.01, respectively. b, PPAR{gamma} protein expression was assessed in mPGES-1 WT and null MEFs treated for 12 h with or without forskolin (10 µM) in the absence or presence of PGE2 (1 µM). Mean ± S.E. for PPAR{gamma} protein expression normalized withbeta-actin from n = 3 separate embryo lines is shown. *, mPGES-1 null MEFs compared with mPGES-1 WT MEFs; +, forskolin- + PGE2-treated group compared with respective unstimulated controls. c, PPAR{gamma} transcriptional activity was measured in the nuclear extracts of mPGES-1 WT and null MEFs treated for 12 h with or without forskolin (10 µM) in the absence or presence of PGE2 (1 µM). Open bars represent mPGES-1 WT MEFs, and closed bars represent mPGES-1 null MEFs. PPAR{gamma} transcriptional activity was normalized to mg of protein for each sample. Data are expressed as the mean ± S.E. for three embryo lines. * and ** indicate statistical significance at p < 0.05 and p < 0.01, respectively.

 
A significant elevation (p < 0.05) in the levels of PGE2 was observed in MEFs upon stimulation with IL-1beta compared with unstimulated MEFs (Fig. 7b). Treatment with rosiglitazone and 15-deoxy-PGJ2 significantly (p < 0.05) blocked the increased production of PGE2 in IL-1beta-stimulated mPGES-1 WT MEFs. This inhibition was recovered when rosiglitazone and 15-deoxy-PGJ2 were used in the presence of GW9662 in IL-1beta-stimulated mPGES-1 WT MEFs. These results show that increased PPAR{gamma} expression results in decreased PGE2 production under basal as well as inflammatory conditions.

Because our results showed that genetic deletion of mPGES-1 and resultant decrease in PGE2 production increased the levels of PPAR{gamma} in MEFs, we expected that mPGES-1 null MEFs would have low levels of COX-2 compared with WT MEFs. Indeed, we observed significantly higher levels of COX-2 protein in mPGES-1 WT MEFs compared with null MEFs under basal conditions (Fig. 7c). These results suggest that increased PPAR{gamma} expression as a result of genetic deletion of mPGES-1 could lead to decreased COX-2 expression in mPGES-1 null MEFs under basal conditions.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
This tudy using MEFs isolated from mPGES-1-deficient mice clearly presents three major conclusions. First, genetic deletion of mPGES-1 results in up-regulation of PPAR{gamma} expression and transcriptional activity under basal conditions. Second, mPGES-1-derived PGE2 is responsible for regulation of PPAR{gamma} expression through a cAMP-independent pathway involving PI 3-kinase and Akt signaling. Third, specific activation of PPAR{gamma} blocks IL-1beta-induced up-regulation of proinflammatory COX-2, mPGES-1, and their derived PGE2 in WT MEFs, whereas increased PPAR{gamma} in mPGES-1 null MEFs is associated with decreased COX-2 expression under basal conditions and after treatment with IL-1beta.


Figure 6
View larger version (81K):
[in this window]
[in a new window]

  		FIGURE 6.
Effect of PI 3-kinase inhibitor (a), Akt inhibitor (b), p38 inhibitor and MEK inhibitor on PPAR{gamma} expression in mPGES-1 WT and null MEFs (c). mPGES-1 WT and null MEFs were incubated for 12 h with LY294002 (30 µM), Akt inhibitor (30 µM), SB203580 (30 µM), and PD98059 (30 µM) in the presence or absence of PGE2, and PPAR{gamma} protein expression was assessed by Western blotting. Mean ± S.E. for PPAR{gamma} protein expression normalized with beta-actin from n = 3 to 5 separate embryo lines is shown. p < 0.05 is considered statistically significant. Cont, control. * mPGES-1 null MEFs compared with mPGES-1 WT MEFs; +, PGE2-treated groups compared with their respective unstimulated controls; $, LY294002- or Akt inhibitor-treated groups compared with their respective unstimulated controls; #, LY294002 + PGE2 or Akt inhibitor- + PGE2-treated groups compared with their respective PGE2-stimulated groups.

 
Differential Regulation of PPAR{gamma} in mPGES-1 Null MEFs—mPGES-1 is an inducible enzyme that acts downstream of COX and specifically catalyzes the conversion of PGH2 to PGE2. Using MEFs isolated from mPGES-1-deficient mice, we have shown previously that in the absence of mPGES-1, low levels of PGE2 are produced under basal as well as cytokine-stimulated conditions (6). In this study, we demonstrate for the first time that genetic deletion of mPGES-1 leads to increased PPAR{gamma} expression and transcriptional activity by eliminating the suppressive effects of PGE2. PPAR{gamma} is a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors that have been shown to initiate mechanisms that inhibit inflammatory responses and assist in the resolution of inflammation (20, 21, 29). Thus inhibition of mPGES-1 not only blocks proinflammatory PGE2 production but also results in the up-regulation of anti-inflammatory PPAR{gamma} in MEFs.

PGE2 Regulates PPAR{gamma} Expression via Non-cAMP Pathway Involving PI 3-Kinase and Akt Signaling—Genetic deletion of specific genes can be associated with unforeseen phenotypic changes. However, we show here that PGE2 is responsible for the differential regulation of PPAR{gamma} expression and transcriptional activity in MEFs. Exogenous PGE2 decreased and NSAIDs (indomethacin, a nonselective COX inhibitor, and NS-398, a selective COX-2 inhibitor) increased PPAR{gamma} under basal conditions confirming that the presence of PGE2 down-regulates PPAR{gamma}, whereas PGE2 depletion results in the up-regulation of PPAR{gamma}.

The next aim of this study was to delineate underlying signaling pathways by which mPGES-1-derived PGE2 regulates PPAR{gamma} expression and transcriptional activity in MEFs. PGE2 exerts the majority of its actions through a family of G protein-coupled receptors, including EP1, EP2, EP3, and EP4 via downstream signaling pathways, including cAMP-dependent protein kinase, MAP kinase, and PI 3-kinase/Akt signaling (8, 30–32).

In this study we first confirmed that the cAMP pathway was intact in mPGES-1 WT and null MEFs. However, forskolin, a direct adenyl cyclase activator, did not lead to any change in PPAR{gamma} expression and transcriptional activity in either mPGES-1 WT or null MEFs in the presence or absence of PGE2. These data suggest that regulation of PPAR{gamma} by mPGES-1-derived PGE2 occurs via a cAMP-independent pathway. No changes in PPAR{gamma} expression were observed following inhibition of MEK or p38 MAP kinase. However, our results clearly show that PI 3-kinase and Akt inhibitors significantly up-regulated PPAR{gamma} expression in mPGES-1 WT MEFs, raising the levels similar to mPGES-1 null MEFs. PI 3-kinase and its immediate downstream effector Akt are therefore the key downstream signaling pathways by which PPAR{gamma} expression is suppressed by PGE2. Various other studies using fibroblasts and other cell types have also shown that PGE2 mediates its regulatory effects on various downstream targets via PI 3-kinase and Akt signaling pathways (33, 34).

Negative Regulation of Proinflammatory COX-2, mPGES-1, and Their Derived PGE2 by PPAR{gamma}—PPAR{gamma} is an endogenous regulator known to mediate its anti-inflammatory effects by down-regulation of proinflammatory mediators (20, 21, 29). In contrast COX-2, mPGES-1, and their derived PGE2 are key proinflammatory mediators involved during initiation of inflammation (1). Using specific PPAR{gamma} agonist (rosiglitazone), PPAR{gamma} ligand (15-deoxy-PGJ2), and PPAR{gamma} inhibitor (GW9662), we observed that specific activation of PPAR{gamma} blocked IL-1beta-induced up-regulation of proinflammatory COX-2, mPGES-1, and their derived PGE2 in WT MEFs. Because of the elevated PPAR{gamma} levels observed upon genetic deletion of mPGES-1, we therefore expected that mPGES-1 null MEFs would have lower levels of COX-2 compared with WT MEFs. Indeed, our results showed significantly lower levels of COX-2 protein in mPGES-1 null MEFs compared with WT MEFs under basal conditions. These results further confirm the endogenous anti-inflammatory properties of PPAR{gamma} in down-regulating key proinflammatory signals.


Figure 7
View larger version (35K):
[in this window]
[in a new window]

  		FIGURE 7.
Effect of PPAR{gamma} on COX-2 and mPGES-1 protein expression and PGE2 levels in MEFs. a, IL-1beta-stimulated and unstimulated mPGES-1 WT MEFs were incubated for 12 h with PPAR{gamma} agonists, rosiglitazone (Ros, 10 µM) and 15-deoxy-PGJ2 (10 µM), in the presence or absence of PPAR{gamma} antagonist GW9662 (3 µM). COX-2, mPGES-1, and beta-actin protein expressions were assessed by Western blotting. Mean ± S.E. for COX-2 and mPGES-1 protein expressions normalized with beta-actin from n = 3 to 4 separate embryo lines is shown. p < 0.05 is considered statistically significant. Cont, control. *, IL-1beta stimulation compared with unstimulated control; +, rosiglitazone + IL-1beta or 15-deoxy-PGJ2 + IL-1beta treated groups compared with their respective IL-1beta-stimulated groups; $, rosiglitazone + GW9662 + IL-1beta or 15-deoxy-PGJ2 + GW9662 + IL-1beta-treated groups compared with rosiglitazone + IL-1beta or 15-deoxy-PGJ2 + IL-1beta-treated groups, respectively. b, levels of PGE2 in supernatants of mPGES-1 WT MEFs were detected by ELISA at 12 h post-IL-1beta stimulation. Closed bars represent mPGES-1 WT MEFs. Data are expressed as the mean ± S.E. for four embryo lines. * and ** indicate statistical significance at p < 0.05 and p < 0.01, respectively. c, COX-2 expression in IL-1beta-stimulated and unstimulated mPGES-1 WT and null MEFs was determined by Western blotting. Mean ± S.E. for COX-2 protein expressions normalized with beta-actin from n = 5 separate embryo lines is shown. *, untreated mPGES-1 null MEFs compared with untreated mPGES-1 WT MEFs.

 
Significance of mPGES-1 Inhibition—PGE2 is a key proinflammatory mediator of inflammation associated with various disease states, and increased PGE2 requires both COX-2 and mPGES-1 (4, 5, 18, 19, 35–38). Nonselective and COX-2-selective NSAIDs reduce PGE2 production by inhibiting COX-2 activity and are extensively used for reducing inflammation, pain, and fever (39). COX-2-specific NSAIDs were developed with improved gastrointestinal safety (40–42). However, recent clinical trials using selective COX-2 inhibitors suggest that specific inhibition of COX-2 is associated with increased incidence of cardiovascular events (11–13). Specific COX-2 inhibition results in loss of anti-thrombotic prostacyclin (PGI2) derived from endothelial COX-2, which plays a key role in the regulation of thrombogenesis (43) and is a possible factor associated with cardiovascular side effects observed with the use of specific COX-2 inhibitors.

mPGES-1 specifically catalyzes the conversion of PGH2 to PGE2, particularly during inflammation, and is an attractive target to achieve more specific inhibition of PGE2 production (3). Recent studies by our group and others (6, 44, 45) have shown that genetic deletion of mPGES-1 results in diversion of prostaglandin production from predominant PGE2 toward PGI2. In addition, we have recently shown that genetic deletion of mPGES-1 results in up-regulation of nitrite levels (stable metabolic product of nitric oxide (NO)) (6). PGI2 and NO are key mediators involved in maintaining vascular homeostasis (46). A recent in vivo study by Fitzgerald and co-workers (45) also showed that mPGES-1 deletion depressed PGE2 and increased PGI2, with no effect on thrombogenesis or blood pressure in mice. Thus, these observations suggest that inhibition of mPGES-1 may avoid the cardiovascular side effects seen with inhibition of COX-2. In addition, this study shows that genetic deletion of mPGES-1 elevates anti-inflammatory PPAR{gamma}. In vitro and in vivo studies suggest that PPAR{gamma} has the ability to stimulate anti-inflammatory responses and assist in the resolution of inflammation by inhibiting a broad range of proinflammatory mediators, including IL-1beta, tumor necrosis factor-{alpha}, and nuclear transcription factor {kappa}B (20, 23, 28, 47). In this study we also demonstrate that PPAR{gamma} has the ability to down-regulate proinflammatory COX-2, mPGES-1, and their derived PGE2 (Fig. 8).


Figure 8
View larger version (18K):
[in this window]
[in a new window]

  		FIGURE 8.
Schematic diagram showing consequences of mPGES-1 deletion on PPAR{gamma}. mPGES-1 deletion decreases proinflammatory PGE2 and its downstream signaling and as a result elevates anti-inflammatory PPAR{gamma}, which has the ability to suppress proinflammatory COX-2, mPGES-1, and their derived PGE2. – represents down-regulation; + represents elevation; dotted arrows represent decrease in PGE2 signaling via EP receptors and its downstream signaling pathways.

 
Although the biology of mPGES-1 and the consequences of blocking its activity have yet to be completely delineated, mPGES-1 remains a viable target. It is not known if the efficacy of such a therapeutic strategy would equal inhibition of COX and all downstream PGs; however, data in mPGES-1 null mice and the efficacy of monoclonal antibodies against PGE2 in an arthritis model (48) offer promise. Studies to date in mPGES-1 null mice and MEFs suggest that inhibiting mPGES-1 may be associated with downstream changes, such as increased NO (6) and PPAR{gamma}, which would promote efficacy and potentially limit adverse effects associated with pharmacological inhibition of mPGES-1.


   FOOTNOTES
 
* This work was supported by the NIAMS Grant R01 AR 049010 from the National Institutes of Health and an Arthritis Foundation Biomedical Sciences grant. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 To whom correspondence should be addressed: Dept. of Internal Medicine, Rheumatology Division, Rm. J-509, KY Clinic, University of Kentucky, Lexington, KY 40536-0284. Tel.: 859-323-4939; Fax: 859-257-8258; E-mail: lcrofford{at}uky.edu.

2 The abbreviations used are: PG, prostaglandin; mPGES-1, microsomal PGE synthase-1; COX, cyclooxygenase; MEF, mouse embryo fibroblast; PPAR{gamma}, peroxisome proliferator-activated receptor {gamma}; PI 3-kinase, phosphatidylinositol 3-kinase; NSAIDs, nonsteroidal anti-inflammatory drugs; DMEM, Dulbecco's modified Eagle's medium; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; WT, wild type; RT, reverse transcription; FBS, fetal bovine serum; IL, interleukin; TBS, Tris-buffered saline; MAP, mitogen-activated protein; ELISA, enzyme-linked immunosorbent assay; MEK, MAP kinase/extracellular signal-regulated kinase kinase. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Crofford, L. J. (2001) Gastroenterol. Clin. North Am. 30, 863–876[CrossRef][Medline] [Order article via Infotrieve]
  2. Kapoor, M., Shaw, O., and Appleton, I. (2005) Curr. Opin. Investig. Drugs 6, 461–466[Medline] [Order article via Infotrieve]
  3. Jakobsson, P. J., Thoren, S., Morgenstern, R., and Samuelsson, B. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 7220–7225[Abstract/Free Full Text]
  4. Kojima, F., Naraba, H., Sasaki, Y., Okamoto, R., Koshino, T., and Kawai, S. (2002) J. Rheumatol. 29, 1836–1842[Abstract/Free Full Text]
  5. Stichtenoth, D. O., Thoren, S., Bian, H., Peters-Golden, M., Jakobsson, P. J., and Crofford, L. J. (2001) J. Immunol. 167, 469–474[Abstract/Free Full Text]
  6. Kapoor, M., Kojima, F., Qian, M., Yang, L., and Crofford, L. J. (2006) FASEB J. 20, 2387–2389[Abstract/Free Full Text]
  7. Murakami, M., Naraba, H., Tanioka, T., Semmyo, N., Nakatani, Y., Kojima, F., Ikeda, T., Fueki, M., Ueno, A., Oh, S., and Kudo, I. (2000) J. Biol. Chem. 275, 32783–32792[Abstract/Free Full Text]
  8. Regan, J. W. (2003) Life Sci. 74, 143–153[CrossRef][Medline] [Order article via Infotrieve]
  9. Fujino, H., Xu, W., and Regan, J. W. (2003) J. Biol. Chem. 278, 12151–12156[Abstract/Free Full Text]
  10. Honda, A., Sugimoto, Y., Namba, T., Watabe, A., Irie, A., Negishi, M., Narumiya, S., and Ichikawa, A. (1993) J. Biol. Chem. 268, 7759–7762[Abstract/Free Full Text]
  11. Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., Konstam, M. A., and Baron, J. A. (2005) N. Engl. J. Med. 352, 1092–1102[Abstract/Free Full Text]
  12. Solomon, S. D., McMurray, J. J., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., and Bertagnolli, M. (2005) N. Engl. J. Med. 352, 1071–1080[Abstract/Free Full Text]
  13. White, W. B., Faich, G., Borer, J. S., and Makuch, R. W. (2003) Am. J. Cardiol. 92, 411–418[CrossRef][Medline] [Order article via Infotrieve]
  14. Kamei, D., Yamakawa, K., Takegoshi, Y., Mikami-Nakanishi, M., Nakatani, Y., Oh-Ishi, S., Yasui, H., Azuma, Y., Hirasawa, N., Ohuchi, K., Kawaguchi, H., Ishikawa, Y., Ishii, T., Uematsu, S., Akira, S., Murakami, M., and Kudo, I. (2004) J. Biol. Chem. 279, 33684–33695[Abstract/Free Full Text]
  15. Trebino, C. E., Stock, J. L., Gibbons, C. P., Naiman, B. M., Wachtmann, T. S., Umland, J. P., Pandher, K., Lapointe, J. M., Saha, S., Roach, M. L., Carter, D., Thomas, N. A., Durtschi, B. A., McNeish, J. D., Hambor, J. E., Jakobsson, P. J., Carty, T. J., Perez, J. R., and Audoly, L. P. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 9044–9049[Abstract/Free Full Text]
  16. Saha, S., Engstrom, L., Mackerlova, L., Jakobsson, P. J., and Blomqvist, A. (2005) Am. J. Physiol. 288, R1100–R1107
  17. Kamei, D., Murakami, M., Nakatani, Y., Ishikawa, Y., Ishii, T., and Kudo, I. (2003) J. Biol. Chem. 278, 19396–19405[Abstract/Free Full Text]
  18. Kojima, F., Naraba, H., Miyamoto, S., Beppu, M., Aoki, H., and Kawai, S. (2004) Arthritis Res. Ther. 6, R355–R365[CrossRef][Medline] [Order article via Infotrieve]
  19. Kojima, F., Naraba, H., Sasaki, Y., Beppu, M., Aoki, H., and Kawai, S. (2003) Arthritis Rheum. 48, 2819–2828[CrossRef][Medline] [Order article via Infotrieve]
  20. Ricote, M., Huang, J. T., Welch, J. S., and Glass, C. K. (1999) J. Leukocyte Biol. 66, 733–739[Abstract]
  21. Fahmi, H., Di Battista, J. A., Pelletier, J. P., Mineau, F., Ranger, P., and Martel-Pelletier, J. (2001) Arthritis Rheum. 44, 595–607[CrossRef][Medline] [Order article via Infotrieve]
  22. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., and Glass, C. K. (1998) Nature 391, 79–82[CrossRef][Medline] [Order article via Infotrieve]
  23. Kawahito, Y., Kondo, M., Tsubouchi, Y., Hashiramoto, A., Bishop-Bailey, D., Inoue, K., Kohno, M., Yamada, R., Hla, T., and Sano, H. (2000) J. Clin. Investig. 106, 189–197[Medline] [Order article via Infotrieve]
  24. Farrajota, K., Cheng, S., Martel-Pelletier, J., Afif, H., Pelletier, J. P., Li, X., Ranger, P., and Fahmi, H. (2005) Arthritis Rheum. 52, 94–104[CrossRef][Medline] [Order article via Infotrieve]
  25. Peng, Y., Liu, H., Liu, F., Wang, H., Liu, Y., and Duan, S. (2005) Hemodial. Int. 9, S15–S20
  26. Moulin, D., Poleni, P. E., Kirchmeyer, M., Sebillaud, S., Koufany, M., Netter, P., Terlain, B., Bianchi, A., and Jouzeau, J. Y. (2006) Biorheology 43, 561–575[Medline] [Order article via Infotrieve]
  27. Cuzzocrea, S., Wayman, N. S., Mazzon, E., Dugo, L., Di Paola, R., Serraino, I., Britti, D., Chatterjee, P. K., Caputi, A. P., and Thiemermann, C. (2002) Mol. Pharmacol. 61, 997–1007[Abstract/Free Full Text]
  28. Willoughby, D. A., Moore, A. R., Colville-Nash, P. R., and Gilroy, D. (2000) Int. J. Immunopharmacol. 22, 1131–1135[CrossRef][Medline] [Order article via Infotrieve]
  29. Sanchez-Hidalgo, M., Martin, A. R., Villegas, I., and Alarcon De La Lastra, C. (2005) Biochem. Pharmacol. 69, 1733–1744[CrossRef][Medline] [Order article via Infotrieve]
  30. Buchanan, F. G., Wang, D., Bargiacchi, F., and DuBois, R. N. (2003) J. Biol. Chem. 278, 35451–35457[Abstract/Free Full Text]
  31. Cheon, H., Rho, Y. H., Choi, S. J., Lee, Y. H., Song, G. G., Sohn, J., Won, N. H., and Ji, J. D. (2006) J. Immunol. 177, 1092–1100[Abstract/Free Full Text]
  32. Sheng, H., Shao, J., Washington, M. K., and DuBois, R. N. (2001) J. Biol. Chem. 276, 18075–18081[Abstract/Free Full Text]
  33. Namkoong, S., Lee, S. J., Kim, C. K., Kim, Y. M., Chung, H. T., Lee, H., Han, J. A., Ha, K. S., Kwon, Y. G., and Kim, Y. M. (2005) Exp. Mol. Med. 37, 588–600[Medline] [Order article via Infotrieve]
  34. Caristi, S., Piraino, G., Cucinotta, M., Valenti, A., Loddo, S., and Teti, D. (2005) J. Biol. Chem. 280, 14433–14442[Abstract/Free Full Text]
  35. Kojima, F., Kato, S., and Kawai, S. (2005) Fundam. Clin. Pharmacol. 19, 255–261[CrossRef][Medline] [Order article via Infotrieve]
  36. Gomez-Hernandez, A., Sanchez-Galan, E., Martin-Ventura, J. L., Vidal, C., Blanco-Colio, L. M., Ortego, M., Vega, M., Serrano, J., Ortega, L., Hernandez, G., Tunon, J., and Egido, J. (2006) J. Cardiovasc. Pharmacol. 47, 60–69[CrossRef][Medline] [Order article via Infotrieve]
  37. Satoh, K., Nagano, Y., Shimomura, C., Suzuki, N., Saeki, Y., and Yokota, H. (2000) Neurosci. Lett. 283, 221–223[CrossRef][Medline] [Order article via Infotrieve]
  38. Kino, Y., Kojima, F., Kiguchi, K., Igarashi, R., Ishizuka, B., and Kawai, S. (2005) Prostaglandins Leukot. Essent. Fatty Acids 73, 103–111[CrossRef][Medline] [Order article via Infotrieve]
  39. Crofford, L. J. (2003) Arthritis Res. Ther. 5, 25–27[Medline] [Order article via Infotrieve]
  40. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., Kvien, T. K., and Schnitzer, T. J. (2000) N. Engl. J. Med. 343, 1520–1528[Abstract/Free Full Text]
  41. Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., Burr, A. M., Zhao, W. W., Kent, J. D., Lefkowith, J. B., Verburg, K. M., and Geis, G. S. (2000) J. Am. Med. Assoc. 284, 1247–1255[Abstract/Free Full Text]
  42. Schnitzer, T. J., Burmester, G. R., Mysler, E., Hochberg, M. C., Doherty, M., Ehrsam, E., Gitton, X., Krammer, G., Mellein, B., Matchaba, P., Gimona, A., and Hawkey, C. J. (2004) Lancet 364, 665–674[CrossRef][Medline] [Order article via Infotrieve]
  43. McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., and FitzGerald, G. A. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 272–277[Abstract/Free Full Text]
  44. Wang, M., Zukas, A. M., Hui, Y., Ricciotti, E., Pure, E., and FitzGerald, G. A. (2006) Proc. Natl. Acad. Sci. U. S. A. 103, 14507–14512[Abstract/Free Full Text]
  45. Cheng, Y., Wang, M., Yu, Y., Lawson, J., Funk, C. D., and Fitzgerald, G. A. (2006) J. Clin. Investig. 116, 1391–1399[CrossRef][Medline] [Order article via Infotrieve]
  46. Olschewski, H., Walmrath, D., Schermuly, R., Ghofrani, A., Grimminger, F., and Seeger, W. (1996) Ann. Intern. Med. 124, 820–824[Abstract/Free Full Text]
  47. Shiojiri, T., Wada, K., Nakajima, A., Katayama, K., Shibuya, A., Kudo, C., Kadowaki, T., Mayumi, T., Yura, Y., and Kamisaki, Y. (2002) Eur. J. Pharmacol. 448, 231–238[CrossRef][Medline] [Order article via Infotrieve]
  48. Portanova, J. P., Zhang, Y., Anderson, G. D., Hauser, S. D., Masferrer, J. L., Seibert, K., Gregory, S. A., and Isakson, P. C. (1996) J. Exp. Med. 184, 883–891[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
E. Kunisch, A. Jansen, F. Kojima, I. Loffler, M. Kapoor, S. Kawai, I. Rubio, L. J. Crofford, and R. W. Kinne
Prostaglandin E2 Differentially Modulates Proinflammatory/Prodestructive Effects of TNF-{alpha} on Synovial Fibroblasts via Specific E Prostanoid Receptors/cAMP
J. Immunol., July 15, 2009; 183(2): 1328 - 1336.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
Y. S. Kim, M. R. Young, G. Bobe, N. H. Colburn, and J. A. Milner
Bioactive Food Components, Inflammatory Targets, and Cancer Prevention
Cancer Prevention Research, March 1, 2009; 2(3): 200 - 208.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
F. Kojima, M. Kapoor, L. Yang, E. L. Fleishaker, M. R. Ward, S. U. Monrad, P. C. Kottangada, C. Q. Pace, J. A. Clark, J. G. Woodward, et al.
Defective Generation of a Humoral Immune Response Is Associated with a Reduced Incidence and Severity of Collagen-Induced Arthritis in Microsomal Prostaglandin E Synthase-1 Null Mice
J. Immunol., June 15, 2008; 180(12): 8361 - 8368.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/8/5356    most recent
M610153200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kapoor, M.
Right arrow Articles by Crofford, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kapoor, M.
Right arrow Articles by Crofford, L. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement